Glycorex Transplantation AB launches new website

Report this content

Glycorex Transplantation launches a new website available at This is an important first step in increasing external communication and visibility in the market and making it easier for customers, partners and investors to find relevant information

With this first version of the new website, we create a starting point for increased communication in general and digital communication in particular. The aim is that both the website and other digital communication platforms should be modern, vibrant and up to date. In addition to creating a website with user-friendly interface, we have given it a new fresh look based on our new graphic profile developed in 2021.

“Communication with our customers, partners, shareholders and investors is very important to us and the website is a central part. When designing the new website, we have considered input from our various stakeholders and followed the current digital communication trends”, says Pontus Nobréus, CEO of Glycorex Transplantation AB.

We have also updated and expanded our presence on social channels. Feel free to follow us on LinkedIn, Twitter and Facebook where we will publish current and interesting news about us, our industry and the world around us.

The goal for the new website is to provide the market with clear information about the company and its operations, ranging from description of products, technology, marketing strategy to financial information. “I am very pleased that we have now launched our new website and welcome both old and new stakeholders to follow our continued development. The website’s new design breathes ambition and confidence, which is in line with the opportunities I see for Glycorex Transplantation”, concludes Pontus Nobréus.


Pontus Nobréus, CEO, Glycorex Transplantation AB
e-mail:, phone: +46 46-286 52 30

Nanosurgical solutions for improved quality of life and better health economy

Glycorex’s unique molecular level nanosurgical technology that specifically selects and removes antibodies in the blood has opened up revolutionary treatments and solutions in healthcare. The company’s medical devices enable transplants across the blood groups saving lives and providing health economic benefits by increasing the number of transplants. The company’s technology to treat blood is applied in several health care settings and a new unique product has recently been launched increasing availability of blood plasma. Several revolutionary products for the treatment of autoimmune diseases are under development.

Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.

For more information:


Documents & Links